- ROIS has acquired an injectable drug-product manufacturing and packaging facility in Phoenix, Arizona, from Bristol Myers Squibb.
- The site adds U.S.-based sterile fill-finish capacity, including plans for up to 70 million pre-filled syringes annually by 2027.
ROIS, the CDMO arm of ROVI, has completed the acquisition of an injectable drug-product manufacturing and packaging facility in Phoenix, Arizona, from Bristol Myers Squibb. The move marks the company’s entry into U.S.-based sterile manufacturing and expands its contract manufacturing network beyond Europe.
The 370,000-square-foot facility has received approximately $100 million in capital investment since 2021 and includes commercial-scale lyophilization capacity and a high-potency cytotoxic area. The site holds regulatory approvals from the FDA, EMA, and Japanese authorities, supporting its role in global supply.
ROIS plans to install an Optima pre-filled syringe isolator line by 2027 in a segregated non-potent area. Once operational, the line is expected to add annual capacity of approximately 65 million to 70 million pre-filled syringes. The plant will support sterile fill-finish and packaging for vials, syringes, and cartridges.
The acquisition follows ROIS’s 2025 rebranding initiative and aligns with its stated goal of expanding its CDMO capabilities. With the addition of the Phoenix site, the company said its network will be capable of producing more than 800 million sterile units per year.
“We are establishing ROIS as a top 3 global CDMO for sterile fill-finish — growing, investing, and expanding capacity to meet our partners’ needs worldwide.”
Kimberlee Steele, Chief Commercial Officer
